Oncologist Hails Tagrisso Approval for 1st-Line Lung Cancer Treatment

Yuichiro Ohe, Chief, Department of Thoracic Oncology, National Cancer Center The use of Tagrisso (osimertinib) in front-line treatment would bring the biggest benefits to patients with EGFR-mutated lung cancer, Yuichiro Ohe, a prominent oncologist at the National Cancer Center (NCC),...read more